Compare GEVO & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEVO | ENGN |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.1M | 605.5M |
| IPO Year | 2010 | N/A |
| Metric | GEVO | ENGN |
|---|---|---|
| Price | $1.87 | $9.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.42 | ★ $22.17 |
| AVG Volume (30 Days) | ★ 2.0M | 223.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $711,000.00 | N/A |
| Revenue This Year | $913.54 | N/A |
| Revenue Next Year | $9.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $2.66 |
| 52 Week High | $2.95 | $12.25 |
| Indicator | GEVO | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 47.58 |
| Support Level | $1.56 | $8.76 |
| Resistance Level | $1.89 | $10.10 |
| Average True Range (ATR) | 0.08 | 0.55 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 67.65 | 25.81 |
Gevo Inc is a next-generation diversified energy company committed to fueling America's future with cost-effective, drop-in fuels that contribute to energy security, abate carbon, and strengthen rural communities to drive economic growth. Its technology can be used to make a variety of renewable products, including sustainable aviation fuel (SAF), motor fuels, chemicals, and other materials that provide U.S.-made solutions. The business model includes developing, financing, and operating production facilities that create jobs and revitalize communities. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.